Status:
COMPLETED
Gefitinib in the Treatment of the First Relapse of Prostate Cancer Beyond Prostatectomy or Radiotherapy
Lead Sponsor:
AstraZeneca
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
PHASE2
Brief Summary
To evaluate activity of gefitinib in subjects with relapsed prostate cancer by estimating PSA response rate at study closure
Eligibility Criteria
Inclusion
- Relapsed prostate cancer after prostatectomy or radiotherapy
- PSA levels below 10 ng/mL
- Lymph node negative
- Metastasis negative
- Withdrawal of hormone therapy at least 6 months before entry into the study
- Written informed consent
Exclusion
- Metastatic disease
- Hormonal treatment 6 months before study entry
- Concomitant radiotherapy, surgery and/or chemotherapy
- ILD
Key Trial Info
Start Date :
December 1 2003
Trial Type :
INTERVENTIONAL
End Date :
October 1 2005
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00241475
Start Date
December 1 2003
End Date
October 1 2005
Last Update
April 23 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Helsinki, Finland